AAAAAA

   
Results: 1-14 |
Results: 14
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs
Authors: Kantor, R Machekano, R Gonzales, MJ Dupnik, K Schapiro, JM Shafer, RW
Citation: R. Kantor et al., Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs, NUCL ACID R, 29(1), 2001, pp. 296-299
Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B (vol 15, pg 1453, 2001)
Authors: Grossman, Z Vardinon, N Chemtob, D Alkan, ML Bentwich, Z Burke, M Gottesman, G Istomin, V Levi, I Maayan, S Shahar, E Schapiro, JM
Citation: Z. Grossman et al., Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B (vol 15, pg 1453, 2001), AIDS, 15(16), 2001, pp. 2209-2209
Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B
Authors: Grossman, Z Vardinon, N Chemtob, D Alkan, ML Bentwich, Z Burke, M Gottesman, G Istomin, V Levi, I Maayan, S Shahar, E Schapiro, JM
Citation: Z. Grossman et al., Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B, AIDS, 15(12), 2001, pp. 1453-1460
Acral purpuric plaques in a woman with asthma: A case of allergic granulomatosis angiitis
Authors: Cohen, C DelVecchio, A Schapiro, JM
Citation: C. Cohen et al., Acral purpuric plaques in a woman with asthma: A case of allergic granulomatosis angiitis, CUTIS, 67(2), 2001, pp. 145
Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study
Authors: Chaix, C Grenier-Sennelier, C Clevenbergh, P Durant, J Schapiro, JM Dellamonica, P Durand-Zaleski, I
Citation: C. Chaix et al., Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study, J ACQ IMM D, 24(3), 2000, pp. 227-231
Persisting long-term benefit of genotype-guided treatment for HIV-infectedpatients failing HAART. The Viradapt study: week 48 follow-up
Authors: Clevenbergh, P Durant, J Halfon, P del Giudice, P Mondain, V Montagne, N Schapiro, JM Boucher, CAB Dellamonica, P
Citation: P. Clevenbergh et al., Persisting long-term benefit of genotype-guided treatment for HIV-infectedpatients failing HAART. The Viradapt study: week 48 follow-up, ANTIVIR TH, 5(1), 2000, pp. 65-70
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the ViradaptStudy
Authors: Durant, J Clevenbergh, P Garraffo, R Halfon, P Icard, S Del Giudice, P Montagne, N Schapiro, JM Dellamonica, P
Citation: J. Durant et al., Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the ViradaptStudy, AIDS, 14(10), 2000, pp. 1333-1339
Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333
Authors: Sevin, AD DeGruttola, V Nijhuis, M Schapiro, JM Foulkes, AS Para, MF Boucher, CAB
Citation: Ad. Sevin et al., Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333, J INFEC DIS, 182(1), 2000, pp. 59-67
Clinical cross-resistance between the HIV-1 protease inhibitors saquinavirand indinavir and correlations with genotypic mutations
Authors: Schapiro, JM Winters, MA Lawrence, J Merigan, TC
Citation: Jm. Schapiro et al., Clinical cross-resistance between the HIV-1 protease inhibitors saquinavirand indinavir and correlations with genotypic mutations, AIDS, 13(3), 1999, pp. 359-365
Drug-resistant genotyping in HIV-1 therapy - Reply
Authors: Durant, J Clevenbergh, PH Schapiro, JM Dellamonica, P
Citation: J. Durant et al., Drug-resistant genotyping in HIV-1 therapy - Reply, LANCET, 354(9184), 1999, pp. 1120-1120
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial
Authors: Durant, J Clevenbergh, P Halfon, P Delgiudice, P Porsin, S Simonet, P Montagne, N Boucher, CAB Schapiro, JM Dellamonica, P
Citation: J. Durant et al., Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial, LANCET, 353(9171), 1999, pp. 2195-2199
Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS Clinical Trials Group 229
Authors: Schapiro, JM Lawrence, J Speck, R Winters, MA Efron, B Coombs, RW Collier, AC Merigan, TC
Citation: Jm. Schapiro et al., Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS Clinical Trials Group 229, J INFEC DIS, 179(1), 1999, pp. 249-253
Frequency of class I HLA-restricted anti-HIV CD8(+) T cells in individualsreceiving highly active antiretroviral therapy (HAART)
Authors: Gray, CM Lawrence, J Schapiro, JM Altman, JD Winters, MA Crompton, M Loi, M Kundu, SK Davis, MM Merigan, TC
Citation: Cm. Gray et al., Frequency of class I HLA-restricted anti-HIV CD8(+) T cells in individualsreceiving highly active antiretroviral therapy (HAART), J IMMUNOL, 162(3), 1999, pp. 1780-1788
Long term effectiveness of Saquinavir and Ritonavir low dosage (baby-dose)in HIV patients failing combination therapy: correlation of response to treatment with genotype mutations and pharmacological data
Authors: Chaillou, S Durant, J Clevenbergh, P Rahelinirina, V Garraffo, R Schapiro, JM Dellamonica, P
Citation: S. Chaillou et al., Long term effectiveness of Saquinavir and Ritonavir low dosage (baby-dose)in HIV patients failing combination therapy: correlation of response to treatment with genotype mutations and pharmacological data, SEVENTH EUROPEAN CONFERENCE ON CLINICAL ASPECTS AND TREATMENT OF HIV-INFECTION, 1999, pp. 69-72
Risultati: 1-14 |